Plausibility and Undue Burden: A New Look at Insufficiency after FibroGen v Akebia
FibroGen Inc. v Akebia Therapeutics Inc. and another company; Astellas Pharma Inc. v Akebia Therapeutics Inc. and other companies [2021] EWCA Civ 1279 What are the
FibroGen Inc. v Akebia Therapeutics Inc. and another company; Astellas Pharma Inc. v Akebia Therapeutics Inc. and other companies [2021] EWCA Civ 1279 What are the
Patent protection remains a crucial form of market exclusivity for new pharmaceutical drugs. But with research time and regulatory requirements delaying entry to market, other
1 Intro Diamonds are forever. Unfortunately, patents are not. This is the sad truth that confronts investors, CEOs and patent managers whose businesses rely heavily
Patent owners will be pleased to know that patents remain unaffected by Brexit because the European Patent Office is not connected to the European Union.
United States
82 Nassau St #60492
New York, NY 10038
__
1 North State Street
15th floor
Chicago, IL 60602
Singapore
7 Temasek Boulevard, #12-07
Suntec Tower One
Israel
2 Yitzhak Rabin
Bet Shemesh
Hong Kong
Tung Wai Commercial Building,
Suite 1404
109-111 Gloucester Road, Wan Chai
Copyright © 2022. All Rights Reserved.